# Accuray Incorporated

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Accuray Incorporated).

## Overview

Accuray Incorporated is a radiation therapy company that develops, manufactures, sells, and supports systems used to deliver highly precise radiation treatments. Its core platforms—CyberKnife and TomoTherapy (including Radixact)—combine treatment delivery hardware with planning and data management software to treat complex cases and streamline more routine cases. The business model is built around capital equipment sales with long, variable sales and installation cycles, supplemented by recurring service, upgrades, and software-related revenue. Accuray sells globally through a mix of direct sales (notably in the U.S. and key international markets) and distributors, with revenue reported across the Americas, EIMEA, Japan, China, and Asia Pacific.

## Products & services

• CyberKnife robotic radiosurgery platform
• TomoTherapy platform (incl. Radixact systems)
• System upgrades and enhancements for installed base
• Service plans: maintenance, warranty, support
• Treatment planning and data management software

- **Radiation therapy platforms (CyberKnife & TomoTherapy/Radixact)** (55%) — Capital sales of radiation treatment systems including delivery hardware and associated system components.
- **Service and support** (30%) — Recurring service plans and support activities including maintenance, warranty, and field service for the installed base.
- **Upgrades and enhancements** (10%) — Hardware and software upgrades, enhancements, and simplifications sold to existing customers to extend system capability and life.
- **Software (planning and data management)** (5%) — Treatment planning and data management software, including capitalized software developed for sale.

- CyberKnife robotic radiosurgery platform
- TomoTherapy platform (including Radixact systems)
- System upgrades and enhancements for installed base
- Service plans (maintenance, warranty, support)
- Treatment planning and data management software

## Customers

Accuray primarily sells to hospitals, cancer treatment centers, and stand-alone radiation therapy facilities that invest in radiation therapy platforms and then operate them over many years. Purchases are typically large, project-based capital decisions influenced by clinical performance, physician adoption, reimbursement dynamics, and the customer’s ability to build or renovate a treatment room for installation. Outside the U.S., sales often occur through distributors, sales agents, and tender processes, which can shift purchasing timing and increase dependence on local regulatory approvals. The company also has concentration risk: it has disclosed that one customer represented 10% or more of total net revenue in multiple fiscal years, making order timing and renewal behavior from that customer important to results.

- **Hospitals and integrated delivery networks** (primary) — Buy platforms plus multi-year service to expand/upgrade radiation oncology capabilities and standardize across sites.
- **Cancer treatment centers and stand-alone clinics** (primary) — Purchase CyberKnife/TomoTherapy systems and upgrades to differentiate on precision, throughput, and treatment flexibility.
- **Government and public-sector healthcare providers** (secondary) — Procure systems through tenders and formal purchasing processes; timing depends on budgets, approvals, and site readiness.
- **Distributors/agents (indirect channel)** (secondary) — Resell into markets where Accuray relies on local coverage, regulatory navigation, and tender participation.
- **Academic and research institutions** (emerging) — Collaborate on research programs and clinical studies that support new indications, evidence generation, and adoption.

- Hospitals buying CyberKnife/TomoTherapy for oncology programs
- Cancer treatment centers seeking precision for complex cases
- Stand-alone radiation therapy facilities expanding capacity
- Government entities purchasing via tenders (often no deposit)
- Large hospital groups/cancer care groups with strong credit
- International buyers served through distributors and agents
- Academic/research institutions collaborating on studies

## Geography

Accuray reports revenue across five regions: the Americas, EIMEA, Japan, China, and Asia Pacific, reflecting a globally distributed customer base. For the nine months ended March 31, 2025, EIMEA was the largest region by net revenue (105.3m), followed by China (93.9m), the Americas (58.4m), Japan (38.2m), and Asia Pacific (35.1m). The company sells directly in the U.S. and maintains international offices in Switzerland (Morges), Hong Kong, Shanghai, and Tokyo, with direct sales staff in much of Western Europe, Japan, India, and Canada. Distributor coverage extends across Europe, Russia, the Middle East, Africa, Asia Pacific, and Latin America, which increases exposure to local regulatory approvals, tender dynamics, and foreign currency movements.

- **Americas** (17.7%) — Nine months ended Mar 31, 2025; based on shipping location
- **EIMEA** (31.8%) — Nine months ended Mar 31, 2025; based on shipping location
- **China** (28.4%) — Nine months ended Mar 31, 2025; based on shipping location
- **Japan** (11.6%) — Nine months ended Mar 31, 2025; based on shipping location
- **Asia Pacific** (10.6%) — Nine months ended Mar 31, 2025; based on shipping location

- Five reporting regions: Americas, EIMEA, Japan, China, Asia Pacific
- EIMEA is a major revenue contributor and spans Europe/India/MEA
- China is a large revenue region, affecting collections and timing
- Direct U.S. selling supplemented by agents and GPO relationships
- International offices: Switzerland, Hong Kong, Shanghai, Tokyo
- Distributors used across EMEA, APAC, Latin America and others
- FX fluctuations can affect backlog conversion and reported revenue

## Strategy

Accuray’s strategy centers on advancing and simplifying its CyberKnife and TomoTherapy/Radixact platforms while supporting a global installed base through service plans, upgrades, and software. Because platform sales can take six to 30 months from first contact to a backlog-qualifying contract, execution priorities include improving sales conversion, managing backlog quality (cancellations/age-outs), and coordinating installation readiness with customers. The company also emphasizes disciplined manufacturing and supply planning—evidenced by inventory build to meet expected demand—while controlling installation, warranty, and maintenance costs. R&D and collaborations with selected hospitals and research institutions are used to validate feasibility, educate physicians, and support regulatory clearances for modifications, upgrades, and new indications.

- **Improve backlog conversion and reduce volatility from long cycles** (short-term) — Revenue recognition depends on site readiness and installation timing, making forecasting and cash flow sensitive to delays and cancellations.
- **Sustain innovation through upgrades, enhancements, and simplification** (medium-term) — Platform competitiveness depends on clinical performance, usability, and the ability to launch enhancements on time and at controlled cost.
- **Scale global commercial coverage via direct and distributor channels** (medium-term) — International growth relies on local market access, tender participation, and regulatory approvals, supported by offices and distributors.

- Drive adoption of CyberKnife and TomoTherapy/Radixact platforms
- Expand recurring revenue via service plans and installed-base upgrades
- Manage long sales/installation cycle and improve backlog conversion
- Invest in R&D and hospital collaborations for evidence and adoption
- Maintain regulatory clearances for upgrades and new indications
- Improve manufacturing yields and delivery/installation execution
- Tighten working capital management (inventory, receivables, payables)

## Risks

Accuray’s revenue is exposed to long and variable sales and installation cycles for CyberKnife and TomoTherapy systems, which can create quarter-to-quarter volatility and make backlog conversion sensitive to customer site readiness. Customer concentration is a disclosed risk, as one customer has represented 10% or more of total net revenue in multiple years, so deferrals or cancellations can materially affect results. The company operates in a heavily regulated environment where upgrades, modifications, and new indications may require FDA 510(k) clearances or other international approvals, and failure to obtain/maintain approvals can block sales in specific countries. Additional risks include cybersecurity threats affecting sensitive data and operations, intellectual property litigation or protection challenges, and compliance risks tied to financial relationships with physicians and customers (e.g., grants, prior loans, volume-related arrangements).

- **Customer concentration and order volatility** [high] — A single customer represented 10% or more of total net revenue in multiple years; reduced orders or deferrals could materially impact results.
- **Backlog conversion and long installation cycle** [high] — Time from first contact to backlog-qualifying contract can be 6–30 months and revenue recognition depends on customer room preparation; cancellations and delays are hard to forecast.
- **Regulatory approval and compliance risk** [high] — Upgrades, modifications, and new indications may require FDA 510(k) or other approvals; failure to obtain/maintain approvals prevents marketing and sales in affected countries.
- **Cybersecurity and sensitive data protection** [medium] — The company regularly experiences cybersecurity incidents and relies on third parties; breaches could disrupt operations and compromise sensitive information/PHI.
- **Intellectual property enforcement and litigation** [medium] — IP is difficult and costly to protect; adverse outcomes in infringement disputes could disrupt component supply or prevent sales of products/components.

- Long sales/installation cycle drives revenue and cash flow volatility
- Backlog conversion risk from cancellations, age-outs, and FX moves
- Customer concentration: one customer ≥10% of revenue in past years
- Regulatory approvals needed for upgrades/new indications (FDA 510(k))
- Cybersecurity incidents could disrupt systems or expose PHI
- IP protection and infringement litigation could restrict product sales
- Compliance risk from physician/customer financial relationships
- Internal control effectiveness risk despite remediation of weaknesses

## Accounting

Accuray’s reported results are sensitive to revenue recognition judgments because platform sales involve multiple elements (systems, installation, service, upgrades) and management must estimate stand-alone selling prices to allocate consideration. The company’s backlog criteria (e.g., deposit/letter of credit in many cases, identified end-customer site, and a 30-month window) affect which orders are included in backlog and how investors interpret future revenue conversion. Inventory valuation is a critical estimate given complex manufacturing, product transitions (phase-in/phase-out), and the risk of inventory overruns tied to new product introductions. Given global sales, foreign currency fluctuations can affect backlog and revenue translation, while collections timing (notably in China per disclosures) can influence receivables and cash flow comparability across quarters.

- **Revenue recognition and stand-alone selling price (SSP)**
- **Inventory valuation and excess/obsolete reserves**

- Revenue recognition depends on SSP estimates across deliverables
- Backlog criteria and age-outs affect visibility into future revenue
- Timing of installation drives point of revenue recognition for systems
- Inventory valuation sensitive to yields, obsolescence, and transitions
- Deferred revenue movements reflect service and contract timing
- FX can affect backlog and reported revenue across regions
- Receivables and collections timing can swing quarterly cash flows

---

*Last updated: 2026-08-11T04:46:16.954977+00:00*